Cybin Inc. Common Stock

HELPNASDAQ • USD
ThemeBiotech - Drug Development›Neuroscience & CNS
4.15 USD
↘ 0.28 (6.32%)AT CLOSE (11:59 AM EDT)
4.10
↘ 0.05 (1.20%)
POST MARKET (AS OF 07:55 PM EDT)
Post Market
AS OF 07:55 PM EDT
4.10
↘ 0.05 (1.20%)
🔴Market: CLOSED
Open?$4.45
High?$4.50
Low?$4.07
Prev. Close?$4.43
Volume?829.9K
Avg. Volume?N/A
VWAP?$4.21
Bid / Ask
Bid?$3.52 × 100
Ask?$4.78 × 100
Spread?$1.26
Midpoint?$4.15
Valuation & Ratios
Market Cap?207.1M
Shares Out?51.6M
Float?50.1M
Float %?100.0%
P/E Ratio?N/A
P/B Ratio?N/A
EPS?N/A
Dividend?N/A
Ex-Dividend?N/A

Shares of Cybin Inc. Common Stock (HELP) are trading at $4.15. The technical outlook is "Strong Sell" based on moving average alignment, RSI, and MACD signals.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
Themes
Biotech - Drug Development›Neuroscience & CNS
Employees
50
Market Cap
207.1M
Industry
N/A
Website
www.helus.com
Listed
2020-11-10
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental Outlook
Loading...
Short InterestElevated
Short % of Float?5.22%Elevated
Short Interest?2.6M
Days to Cover?3.3
Free Float50.1M
Avg Daily Volume785.8K
Settlement Date2026-05-15
MarketsMoversWatchlist